Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Asahi Kasei Banks on Tarpeyo to Hit 300 Billion Yen in Pharma Sales by FY2030
Japanese chemical conglomerate Asahi Kasei is positioning its IgA nephropathy drug Tarpeyo (budesonide) as a key growth driver as it works toward its goal of more than 300 billion yen in pharmaceutical sales by FY2030, top company officials said in…
To read the full story
Related Article
- Asahi Kasei Pharma to Rebrand as Asahi Kasei Therapeutics in April
March 6, 2026
- Asahi Kasei to Buy German Antiviral Specialist Aicuris for 143.1 Billion Yen
February 27, 2026
- Okajima to Take Helm of Asahi Kasei Pharma in April
February 6, 2026
- Asahi Kasei Sees Tarpeyo Uptake Outpacing Forecast, Peak Sales Can Be Higher
January 9, 2026
BUSINESS
- J-Pharma Goes Public on TSE, Eyes Licensing of LAT1 Inhibitors
March 26, 2026
- Asahi Kasei Banks on Tarpeyo to Hit 300 Billion Yen in Pharma Sales by FY2030
March 26, 2026
- Takeda Unveils Annual 200 Billion Yen Cost Savings by FY2028
March 26, 2026
- SanBio Targets Akuugo Shipments after May NHI Listing
March 26, 2026
- Tracleer Generics Add Digital Ulcer Prevention Use
March 26, 2026
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…